PolyPid Ltd. (PYPD)
- Previous Close
4.6700 - Open
4.3530 - Bid --
- Ask --
- Day's Range
4.3530 - 4.3530 - 52 Week Range
3.5660 - 13.2000 - Volume
535 - Avg. Volume
3,183 - Market Cap (intraday)
20.882M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-16.9900 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.33
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
www.polypid.comRecent News: PYPD
Performance Overview: PYPD
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYPD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYPD
Valuation Measures
Market Cap
22.75M
Enterprise Value
19.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.18
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.14%
Return on Equity (ttm)
-1,278.60%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.86M
Diluted EPS (ttm)
-16.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
5.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.27M
Research Analysis: PYPD
Company Insights: PYPD
PYPD does not have Company Insights